Abstract

Case Report

Systemic sclerosis sine scleroderma presenting as renal crisis, a case report and review of the literature

Urvi V Patel, Navdeep Sangha* and Andrew Rettew

Published: 17 April, 2023 | Volume 7 - Issue 1 | Pages: 001-010

Systemic sclerosis sine scleroderma is a rare subset of systemic sclerosis with isolated organ involvement. Scleroderma renal crisis is a severe manifestation of systemic sclerosis characterized by malignant hypertension, oligo/anuric renal failure, and thrombotic microangiopathy. We present a case of a 55-year-old male with uncontrolled hypertension who presented with hematospermia and was found to have acute renal failure, microangiopathic hemolytic anemia, concerning thrombotic microangiopathy. Empiric management for thrombotic thrombocytopenic purpura (TTP) with plasma exchange and corticosteroids yielded a paradoxical response, ultimately leading to the diagnosis of systemic sclerosis sine scleroderma presenting as scleroderma renal crisis (SRC) after serological confirmation. Given the morbidity and mortality associated with scleroderma renal crisis, it should be increasingly considered as a differential for thrombotic microangiopathy even without outward manifestations of systemic sclerosis. Additionally, the empiric management of TTP can include the use of corticosteroids which can exacerbate SRC, an early clinical clue in the diagnosis of this disease.

Read Full Article HTML DOI: 10.29328/journal.jhcr.1001021 Cite this Article Read Full Article PDF

Keywords:

Systemic sclerosis sine scleroderma; Scleroderma renal crisis; Thrombotic microangiopathy

References

  1. McCray CJ, Mayes MD. Update on systemic sclerosis. Curr Allergy Asthma Rep. 2015 May;15(5):25. doi: 10.1007/s11882-015-0526-0. PMID: 26139334.
  2. Lee CM, Girnita D, Sharma A, Khanna S, Elwing JM. A Unique Presentation of Anti-RNA Polymerase III Positive Systemic Sclerosis Sine Scleroderma. Case Rep Rheumatol. 2016;2016:8536341. doi: 10.1155/2016/8536341. Epub 2016 Jul 31. PMID: 27559487; PMCID: PMC4983352.
  3. Sobolewski P, Maślińska M, Wieczorek M, Łagun Z, Malewska A, Roszkiewicz M, Nitskovich R, Szymańska E, Walecka I. Systemic sclerosis - multidisciplinary disease: clinical features and treatment. Reumatologia. 2019;57(4):221-233. doi: 10.5114/reum.2019.87619. Epub 2019 Aug 31. PMID: 31548749; PMCID: PMC6753596.
  4. Zanatta E, Polito P, Favaro M, Larosa M, Marson P, Cozzi F, Doria A. Therapy of scleroderma renal crisis: State of the art. Autoimmun Rev. 2018 Sep;17(9):882-889. doi: 10.1016/j.autrev.2018.03.012. Epub 2018 Jul 10. PMID: 30005860.
  5. Zanatta E, Codullo V, Allanore Y. Scleroderma renal crisis: Case reports and update on critical issues. Eur J Rheumatol. 2021 Jul;8(3):162-167. doi: 10.5152/eurjrheum.2020.20048. PMID: 33226326; PMCID: PMC9770404.
  6. Zuckerman R, Asif A, Costanzo EJ, Vachharajani T. Complement activation in atypical hemolytic uremic syndrome and scleroderma renal crisis: a critical analysis of pathophysiology. J Bras Nefrol. 2018 Jan-Mar;40(1):77-81. doi: 10.1590/2175-8239-JBN-3807. Epub 2018 May 7. PMID: 29796581; PMCID: PMC6533968.
  7. Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Moinzadeh P, Müller-Ladner U, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkoetter C, Weber M, Worm M, Klaus P, Rubbert A, Steinbrink K, Grundt B, Hein R, Scharffetter-Kochanek K, Hinrichs R, Walker K, Szeimies RM, Karrer S, Müller A, Seitz C, Schmidt E, Lehmann P, Foeldvári I, Reichenberger F, Gross WL, Kuhn A, Haust M, Reich K, Böhm M, Saar P, Fierlbeck G, Kötter I, Lorenz HM, Blank N, Gräfenstein K, Juche A, Aberer E, Bali G, Fiehn C, Stadler R, Bartels V; Registry of the German Network for Systemic Scleroderma. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford). 2008 Aug;47(8):1185-92. doi: 10.1093/rheumatology/ken179. Epub 2008 May 31. PMID: 18515867; PMCID: PMC2468885.
  8. Gallan AJ, Chang A. A New Paradigm for Renal Thrombotic Microangiopathy. Semin Diagn Pathol. 2020 May;37(3):121-126. doi: 10.1053/j.semdp.2020.01.002. Epub 2020 Feb 6. PMID: 32085935.
  9. Tostivint I, Mougenot B, Flahault A, Vigneau C, Costa MA, Haymann JP, Sraer JD, Rondeau E. Adult haemolytic and uraemic syndrome: causes and prognostic factors in the last decade. Nephrol Dial Transplant. 2002 Jul;17(7):1228-34. doi: 10.1093/ndt/17.7.1228. PMID: 12105245.
  10. Devresse A, Aydin S, Le Quintrec M, Demoulin N, Stordeur P, Lambert C, Gastoldi S, Pirson Y, Jadoul M, Morelle J. Complement activation and effect of eculizumab in scleroderma renal crisis. Medicine (Baltimore). 2016 Jul;95(30):e4459. doi: 10.1097/MD.0000000000004459. PMID: 27472742; PMCID: PMC5265879.
  11. Chua JS, Baelde HJ, Zandbergen M, Wilhelmus S, van Es LA, de Fijter JW, Bruijn JA, Bajema IM, Cohen D. Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy. J Am Soc Nephrol. 2015 Sep;26(9):2239-47. doi: 10.1681/ASN.2014050429. Epub 2015 Jan 8. PMID: 25573909; PMCID: PMC4552108.
  12. Teoh CW, Riedl M, Licht C. The alternative pathway of complement and the thrombotic microangiopathies. Transfus Apher Sci. 2016 Apr;54(2):220-31. doi: 10.1016/j.transci.2016.04.012. Epub 2016 Apr 26. PMID: 27160864.
  13. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010 Jan 14;115(2):379-87. doi: 10.1182/blood-2009-05-221549. Epub 2009 Oct 27. PMID: 19861685; PMCID: PMC2829859.
  14. Zhang Y, Ghiringhelli Borsa N, Shao D, Dopler A, Jones MB, Meyer NC, Pitcher GR, Taylor AO, Nester CM, Schmidt CQ, Smith RJH. Factor H Autoantibodies and Complement-Mediated Diseases. Front Immunol. 2020 Dec 15;11:607211. doi: 10.3389/fimmu.2020.607211. PMID: 33384694; PMCID: PMC7770156.
  15. Guerra SG, Fonseca C, Nihtyanova SI, Stern E, Abraham DJ, Burns A, Harber M, Denton CP. Defining genetic risk for scleroderma renal crisis: a genome-wide analysis of anti-RNA polymerase antibody-positive systemic sclerosis. British Journal of Rheumatology. 2015; 54(1): 159-159. https://doi.org/1093/rheumatology/kev090.047.
  16. Okrój M, Johansson M, Saxne T, Blom AM, Hesselstrand R. Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis. Arthritis Res Ther. 2016 Nov 18;18(1):267. doi: 10.1186/s13075-016-1168-x. PMID: 27863511; PMCID: PMC5116178.
  17. Hirose Y, Yoshida Y, Konda S, Tanaka N, Hirone T. Pernicious anemia in a patient with progressive systemic sclerosis. Nihon Ketsueki Gakkai Zasshi. 1977 Feb;40(1):1-8. PMID: 577644.
  18. Lee H, Kang E, Kang HG, Kim YH, Kim JS, Kim HJ, Moon KC, Ban TH, Oh SW, Jo SK, Cho H, Choi BS, Hong J, Cheong HI, Oh D. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020 Jan;35(1):25-40. doi: 10.3904/kjim.2019.388. Epub 2020 Jan 2. PMID: 31935318; PMCID: PMC6960041.

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?